We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind?
Read MoreHide Full Article
Key Takeaways
AEHR trades at 18.59X forward sales after a 363% 2026 surge, leaving little room for disappointment.
Aehr entered fiscal 2027 with $100.6M in backlog, supporting its $130M-$150M revenue outlook.
AEHR's top five customers drove roughly 70% of fiscal 2026 revenue, heightening order and execution risk.
Aehr Test Systems, Inc. (AEHR - Free Report) has become a semiconductor winner in 2026, but expectations now leave little room for disappointment. Investors are weighing two possibilities. Either the market is still catching up to Aehr’s expanding role in AI-related semiconductor testing, or the share price has moved too far ahead of what the business has proved so far.
A Premium Valuation Sets a High Bar
AEHR currently trades at a forward 12-month price-to-sales multiple of 18.59X. That is more than three times its three-year median of 6.05X and well above the broader industry’s average of 5.43X. The gap is also clear against peers. Teradyne, Inc. (TER - Free Report) trades at 10.08X, while Cohu, Inc. (COHU - Free Report) trades at 3.86X.
The premium leaves little room for shortfalls in bookings, revenue or margins. AEHR’s Value Score of F reinforces the view that the stock is expensive on valuation measures.
Image Source: Zacks Investment Research
Wall Street Still Sees More Upside
Analyst sentiment remains positive despite the elevated multiple. AEHR trades below the average analyst price target of $128, implying about 41.4% upside. The high target stands at $175, while the low target is $110. The wide target range highlights uncertainty over how much future growth is already priced in and whether Aehr can deliver consistently.
AEHR Stock Has Already Repriced the Story
AEHR shares have surged 363% so far this year, far outpacing the industry’s 58.2% growth and the S&P 500’s 11.5% advance. The stock has also beaten Teradyne, up 91.9%, and Cohu, up 148.2%, over the same period.
AEHR entered 2026 weighed down by weak EV-related SiC demand. Its rapid shift toward AI applications has since reshaped the market’s view of the company.
AEHR YTD Performance Vs. TER, COHU, Industry & S&P 500
Image Source: Zacks Investment Research
A Stronger Balance Sheet Supports the Ramp
Aehr ended May 29, 2026, with $116.4 million in cash and cash equivalents, up from $24.5 million a year earlier. Total liabilities stood at $27.2 million. The cash build, supported by equity financing, gives the company flexibility as it prepares for a much larger revenue base. It can fund working-capital needs and support higher production levels.
AI is Driving the Next Phase
The clearest source of growth is AI-related semiconductor testing.Its lead wafer-level AI account is expanding production capacity, supporting demand for FOX-XP systems and WaferPak contactors, while a separate hyperscale customer is scaling package-level burn-in for custom AI processors using Sonoma systems.
Silicon photonics is opening another growth avenue as AI data centers adopt faster optical interconnects. Aehr's lead customer is increasing production, and a newer networking customer has also moved into follow-on system orders for hyperscale deployments.
Silicon carbide offers an additional source of recovery, particularly in electric vehicles, while growing AI data-center power requirements could support renewed demand for both SiC and GaN test solutions.
Aehr is also developing wafer-level burn-in opportunities in memory, including NAND and potential HBM applications. The company is working with multiple memory suppliers, although this remains an early-stage opportunity and is not yet a meaningful contributor to current guidance.
Aehr entered fiscal 2027 with $100.6 million of effective backlog, supporting visibility into its $130-$150 million revenue outlook. Subsequent AI and silicon-photonics production orders further strengthened its order pipeline.
Estimates for AEHR Point to Another Big Step Up
For fiscal 2027, the Zacks Consensus Estimate for Aehr Test Systems’ EPS is projected at 74 cents, a sharp increase from 3 cents a year ago. For fiscal 2028, the estimate is pegged at $1.54, indicating another 108.8% increase. Moreover, analysts project fiscal 2027 revenues of $140.75 million, up 181.5%, followed by $216.67 million in fiscal 2028, implying another 53.9% increase.
Aehr beat earnings estimates in three of the past four quarters and matched once, producing an average earnings surprise of 321.9%.
Aehr Test Systems Price, Consensus and EPS Surprise
Customer concentration remains a key risk for AEHR. Its five largest customers accounted for roughly 70% of fiscal 2026 revenues, leaving results exposed to shifts in production schedules or spending by a small group of customers. Given the high value of individual system orders, even modest delays or rescheduling can create significant quarterly volatility.
AEHR also remains exposed to semiconductor capital-spending cycles. AI and data-center demand is strong, but equipment spending remains uneven, and orders can shift between quarters.The company itself cautions that backlog does not necessarily translate directly into future revenues.
Execution risk has increased alongside expectations. While manufacturing capacity has been expanded, the company must convert demand into timely shipments and profitable growth while managing supplier and component constraints. After the stock’s sharp rally, setbacks in orders, deliveries or margins could trigger an outsized market reaction.
Conclusion
Aehr’s growth outlook has strengthened, supported by AI demand, silicon photonics, a recovering SiC business and a sizable backlog. Still, the stock’s strong run has pushed valuation to demanding levels, leaving less room for execution missteps.
Customer concentration, lumpy semiconductor spending and the need to convert backlog into profitable growth remain key risks. With strong revenue and earnings growth already reflected in expectations, the risk-reward looks more balanced at current levels. AEHR currently carries a Zacks Rank #3 (Hold), suggesting investors may want to wait for a better entry point or clearer evidence of sustained execution. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind?
Key Takeaways
Aehr Test Systems, Inc. (AEHR - Free Report) has become a semiconductor winner in 2026, but expectations now leave little room for disappointment. Investors are weighing two possibilities. Either the market is still catching up to Aehr’s expanding role in AI-related semiconductor testing, or the share price has moved too far ahead of what the business has proved so far.
A Premium Valuation Sets a High Bar
AEHR currently trades at a forward 12-month price-to-sales multiple of 18.59X. That is more than three times its three-year median of 6.05X and well above the broader industry’s average of 5.43X. The gap is also clear against peers. Teradyne, Inc. (TER - Free Report) trades at 10.08X, while Cohu, Inc. (COHU - Free Report) trades at 3.86X.
The premium leaves little room for shortfalls in bookings, revenue or margins. AEHR’s Value Score of F reinforces the view that the stock is expensive on valuation measures.
Wall Street Still Sees More Upside
Analyst sentiment remains positive despite the elevated multiple. AEHR trades below the average analyst price target of $128, implying about 41.4% upside. The high target stands at $175, while the low target is $110. The wide target range highlights uncertainty over how much future growth is already priced in and whether Aehr can deliver consistently.
AEHR Stock Has Already Repriced the Story
AEHR shares have surged 363% so far this year, far outpacing the industry’s 58.2% growth and the S&P 500’s 11.5% advance. The stock has also beaten Teradyne, up 91.9%, and Cohu, up 148.2%, over the same period.
AEHR entered 2026 weighed down by weak EV-related SiC demand. Its rapid shift toward AI applications has since reshaped the market’s view of the company.
AEHR YTD Performance Vs. TER, COHU, Industry & S&P 500
A Stronger Balance Sheet Supports the Ramp
Aehr ended May 29, 2026, with $116.4 million in cash and cash equivalents, up from $24.5 million a year earlier. Total liabilities stood at $27.2 million. The cash build, supported by equity financing, gives the company flexibility as it prepares for a much larger revenue base. It can fund working-capital needs and support higher production levels.
AI is Driving the Next Phase
The clearest source of growth is AI-related semiconductor testing.Its lead wafer-level AI account is expanding production capacity, supporting demand for FOX-XP systems and WaferPak contactors, while a separate hyperscale customer is scaling package-level burn-in for custom AI processors using Sonoma systems.
Silicon photonics is opening another growth avenue as AI data centers adopt faster optical interconnects. Aehr's lead customer is increasing production, and a newer networking customer has also moved into follow-on system orders for hyperscale deployments.
Silicon carbide offers an additional source of recovery, particularly in electric vehicles, while growing AI data-center power requirements could support renewed demand for both SiC and GaN test solutions.
Aehr is also developing wafer-level burn-in opportunities in memory, including NAND and potential HBM applications. The company is working with multiple memory suppliers, although this remains an early-stage opportunity and is not yet a meaningful contributor to current guidance.
Aehr entered fiscal 2027 with $100.6 million of effective backlog, supporting visibility into its $130-$150 million revenue outlook. Subsequent AI and silicon-photonics production orders further strengthened its order pipeline.
Estimates for AEHR Point to Another Big Step Up
For fiscal 2027, the Zacks Consensus Estimate for Aehr Test Systems’ EPS is projected at 74 cents, a sharp increase from 3 cents a year ago. For fiscal 2028, the estimate is pegged at $1.54, indicating another 108.8% increase. Moreover, analysts project fiscal 2027 revenues of $140.75 million, up 181.5%, followed by $216.67 million in fiscal 2028, implying another 53.9% increase.
Aehr beat earnings estimates in three of the past four quarters and matched once, producing an average earnings surprise of 321.9%.
Aehr Test Systems Price, Consensus and EPS Surprise
Aehr Test Systems price-consensus-eps-surprise-chart | Aehr Test Systems Quote
What Could Go Wrong
Customer concentration remains a key risk for AEHR. Its five largest customers accounted for roughly 70% of fiscal 2026 revenues, leaving results exposed to shifts in production schedules or spending by a small group of customers. Given the high value of individual system orders, even modest delays or rescheduling can create significant quarterly volatility.
AEHR also remains exposed to semiconductor capital-spending cycles. AI and data-center demand is strong, but equipment spending remains uneven, and orders can shift between quarters.The company itself cautions that backlog does not necessarily translate directly into future revenues.
Execution risk has increased alongside expectations. While manufacturing capacity has been expanded, the company must convert demand into timely shipments and profitable growth while managing supplier and component constraints. After the stock’s sharp rally, setbacks in orders, deliveries or margins could trigger an outsized market reaction.
Conclusion
Aehr’s growth outlook has strengthened, supported by AI demand, silicon photonics, a recovering SiC business and a sizable backlog. Still, the stock’s strong run has pushed valuation to demanding levels, leaving less room for execution missteps.
Customer concentration, lumpy semiconductor spending and the need to convert backlog into profitable growth remain key risks. With strong revenue and earnings growth already reflected in expectations, the risk-reward looks more balanced at current levels. AEHR currently carries a Zacks Rank #3 (Hold), suggesting investors may want to wait for a better entry point or clearer evidence of sustained execution. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.